Oncopeptides Logo
SE0009414576
A2DLU2
ONCO.ST

Oncopeptides

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Oncopeptides: revenue in second quarter rises 62%, shares jump

    Oncopeptides reported net sales of SEK 31.1m in Q2 2026, up 62% year‑on‑year, and SEK 56.5m in the first half (+74%). Gross margin in H1 was 98%, the EBIT loss narrowed to SEK 86.2m, and operating costs fell slightly. The company reported SEK 158m in cash after a March rights issue and reiterated its target to reach positive cash flow in 2027. The share rose about 10% in early trading but remains well below the 52‑week high. » Altro su de.investing.com


  • Oncopeptides: Q3 revenue rises 174% – profitability targeted by end of 2026

    Oncopeptides reports Q3 2025 revenue of SEK 20.2m, up 174% year‑on‑year, and a gross margin of 99%. EBIT improved to -SEK 47.1m but remained negative, while operating expenses were slightly reduced. After an oversubscribed rights issue, liquidity stands at SEK 147.9m; the company aims for positive cash flow by the end of 2026. Oncopeptides is advancing commercialization in Europe (Germany, Spain, Italy) and is negotiating partnerships in Japan, but uncertainty over growth and timing failed to reassure investors, sending the stock down nearly 14%. » Altro su de.investing.com


  • Oncopeptides achieves 174% revenue increase, stock falls sharply in pre-market

    Oncopeptides reported Q3 2025 net revenue growth of 174% to SEK 20.2m and a gross profit of SEK 19.9m with a gross margin of 99%. Operating expenses fell 3% and EBIT improved from -SEK 61.3m to -SEK 47.1m; after a capital raise liquidity stands at SEK 147.9m. Despite the progress, the stock fell 12.44% in pre-market trading as investors voiced concerns about operational challenges, market expansion and the timeline to profitability by end-2026. Management plans to expand its market presence in Europe and will present further details at the capital markets day on 13 November. » Altro su de.investing.com


  • Oncopeptides reports strong Q2 growth, plans SEK 150m rights issue

    Oncopeptides posted net sales of SEK 19.2m in Q2 2025 (+45% q/q, +135% y/y) and has recorded three quarters with >30% growth, while the stock fell sharply in pre-market trading. The company plans a rights issue of SEK 150m, holds SEK 70m in cash and is targeting positive cash flow by 2026. Pepaxti was included in EMN guidelines and approved in markets such as Germany, Spain and Italy; partnership negotiations for Japan are ongoing. » Altro su de.investing.com

Dati finanziari

Nell'ultimo trimestre, Oncopeptides ha registrato ricavi pari a 2,51 Mln € e un utile netto di -3,88 Mln €

(EUR) settembre 2026
YoY
Ricavi 2,51 Mln 37,22%
Utile lordo 2,47 Mln 36,92%
Utile netto -3,88 Mln 29,60%
EBITDA -3,17 Mln 24,62%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
63,03 Mln €
Numero di azioni
431,36 Mln
Massimo/minimo a 52 settimane
0,52 € - 0,11 €
Dividendi No
Beta
-1,41
Rapporto P/E
-2,60
Rapporto PEG
-0,03
Rapporto P/B
-36,43
Rapporto P/S
6,83

Profilo aziendale

Oncopeptides AB (publ), una società biotecnologica, sviluppa farmaci per il trattamento del cancro negli Stati Uniti, in Europa e a livello internazionale. Il suo principale candidato prodotto è melflufen, un farmaco coniugato peptidico antitumorale per il trattamento del mieloma multiplo recidivante e refrattario in pazienti adulti. Oncopeptides AB (publ) è stata costituita nel 2000 e ha sede a Stoccolma, in Svezia.

Nome
Oncopeptides
CEO
Sofia Heigis
Sede centrale Stockholm, ab
Svezia
Sito web
Quotazione in borsa
22/02/2017
Dipendenti 71

Simboli di borsa

Borsa Simbolo
Sto
ONCO.ST
Pnk
ONPPF
Frankfurt
OND.F
Düsseldorf
OND.DU
London
0RN4.L
Stockholm
ONCO.ST
München
OND.MU
🍪

Parqet  usa i cookie. Scopri di più